Welcome to the 2020 ABTA National Conference

Dear Conference Attendees,

Welcome to the American Brain Tumor Association's 27th Annual National Conference. On behalf of the ABTA staff and Board of Directors, we’re proud to present this educational meeting in a virtual format during these uncertain times. While the pandemic impacts us all, we must remember that approximately 700 children and adults are diagnosed with a primary or metastatic brain tumor every day. These are uncertain times, but one thing is certain, the ABTA will not waiver in our shared commitment to serving our brain tumor community.

The ABTA National Conference is the largest brain tumor educational conference specifically designed for patients, caregivers and survivors, across all ages and tumor types. Our goal is to give you access to our nation’s leading medical and research experts to empower you with the information you need to navigate the physical and emotional journey of a brain tumor diagnosis. Thanks to our presenting sponsor, The Sontag Foundation, and our other generous sponsors, we are proud to offer this best-in-class educational conference for free.

This conference would not be possible without the leadership and dedication of our National Conference Co-chairs, Mark R. Gilbert, MD., Chief and Sr. Investigator, The Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health and Jean Arzbaecher, RN, APN, CNRN, Advanced Practice Nurse, The University of Illinois at Chicago. They invested significant time and attention to reformatting our meeting program from an in-person to virtual format to ensure the program is engaging and informative.

We look forward to spending this time with you. Be sure to visit our website, abta.org, to learn more about the resources and services available to you and the many ways in which you can participate in the ABTA’s efforts to advance the understanding and treatment of brain tumors.

Kind regards,

Ralph A. DeVitto
President & CEO
American Brain Tumor Association
CONFERENCE CO-CHAIR GREETING

Dear Conference Attendees,

We want to give you our sincerest welcome to the American Brain Tumor Association 2020 Virtual National Conference. We recognize that the current situation prevents us from all gathering together and we know that those who have participated in prior conferences share our disappointment in not being able to network in person. However, we are both pleased and excited to provide an outstanding program designed to inform and support you along your journey. Lecture topics will discuss treatment advancements for a variety of brain tumors, strategies to manage day-to-day symptoms and concerns, survivorship, emerging technologies, and much more.

Although the meeting will be virtual, we are encouraging you to be fully engaged. In that context, we invite you to ask questions and share your experiences throughout the conference. As you can see from the Agenda, the conference includes other invaluable experiences, including a variety of educational resources from our sponsors, poster presentations from our researchers, an opportunity to hear from patients and caregivers as they are living with a brain tumor, and a Key Note Address from Maria Menounos, Emmy® Award-winning journalist, author and actress and brain tumor survivor. We hope this conference will be an invaluable and enriching experience.

Thank you so much for participating. We are really looking forward to spending time with you.

Sincerely,
ABTA National Conference Co-Chairs
Mark R. Gilbert, MD and Jean Arzbaecher, RN, APN, CNRN
Joel A. Gingras Jr. Award Recipient
Priscilla Brastianos, MD
Director, Central Nervous System Metastasis Center
Massachusetts General Hospital / Harvard Medical Center

Originally from Vancouver, British Columbia, Dr. Priscilla Brastianos received her BSc in biochemistry and chemistry from the University of British Columbia. Dr. Priscilla Brastianos completed her medical school and internal medicine residency at Johns Hopkins School of Medicine. She first received ABTA funding as a medical student which helped propel her career in brain tumor research, and she has been part of the ABTA community since then! She completed her fellowship training in hematology/oncology and neuro-oncology at the Dana-Farber Cancer Institute and Massachusetts General Hospital, during which time she received an ABTA basic research fellowship.

With ABTA funding she made seminal contributions to the field of brain metastasis research, demonstrating that brain metastases genetically diverge from primary tumors and harbor clinically actionable mutations. She is now director of the Central Nervous System Metastasis Center at Massachusetts General Hospital and leads an R01-funded laboratory. Dr. Brastianos has mentored several early-career scientists who were awarded ABTA fellowships.

Her research focuses on understanding the genomic mechanisms that drive primary and metastatic brain tumors. She has lead studies which have identified novel therapeutic targets in brain tumors and has translated her scientific findings to national multicenter trials. Dr. Brastianos also leads a multidisciplinary central nervous system metastasis clinic at Massachusetts General Hospital/Harvard Medical School. She has received a number of awards for her work including a ‘NextGen Star’ award by the American Association for Cancer Research, a Damon Runyon Clinical Investigator Award, a Breast Cancer Research Foundation Award and a Susan G. Komen Career Catalyst Award. Her patients inspire her every day to look for better treatments for patients with brain tumors.

Keynote Speaker
Maria Menounos

Maria Menounos, Emmy® Award-winning journalist, author and actress, has earned numerous achievements throughout her career in the news and entertainment industry. She’s been on the line to report breaking news and interview presidential candidates, and now she adds the roles of brain tumor survivor and caregiver.

In early 2017, Maria started experiencing symptoms of her own as she was caring for her mother, who was diagnosed with a glioblastoma brain tumor a few months prior. Maria thought it was stress from caregiving. After a visit with her primary care doctor, they decided to get an MRI. The MRI showed Maria had a golf-ball-sized meningoimia, a brain tumor located in the membrane surrounding the brain and spinal cord. “I didn’t cry. I actually laughed. It was so surreal and unbelievable that my mom had a brain tumor—and now I had one too,” Maria said.

Maria found herself in the unlikely circumstance of going from caregiver to patient. One month later, Maria had nearly all of her tumor removed and lives each day with the promise of tomorrows. She’s now turned coach and advocate for others fighting brain tumors, all while balancing the demands of her public life on TV and radio.
### PROGRAM AGENDA

**Friday, September 11**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:20 AM</td>
<td><strong>Welcome/Opening Remarks</strong>&lt;br&gt;Jim Reilly, ABTA Board Chair&lt;br&gt;Mark R. Gilbert, MD&lt;br&gt;Jean Arzbaecher, RN, APN, CNRN</td>
</tr>
<tr>
<td>Central Time (CT)</td>
<td><strong>ABTA Session: Who We Are, What We Offer &amp; How to Get Involved</strong>&lt;br&gt;Introductions by: Brandon Starkoff, ABTA Vice Chair&lt;br&gt;Nicole Willmarth, PhD, ABTA Chief Mission Officer&lt;br&gt;Alicia Morris, ABTA Director, National Volunteers&lt;br&gt;Learn more about invaluable ABTA resources and programs offered to patients, caregivers and families that can provide support along the trajectory of a brain tumor diagnosis.</td>
</tr>
<tr>
<td>10:50 - 10:55 AM</td>
<td><strong>Break featuring:</strong>&lt;br&gt;&lt;br&gt;<em>Sponsor:</em>&lt;br&gt;Northwestern Medicine&lt;br&gt;<strong>Multi-disciplinary Team Approach to Treating Brain Tumors: A Brain Tumor Patient Story</strong>&lt;br&gt;Roger Stupp, MD; Rimas Lukas, MD; Virginia B. Hill, MD; Maciej S. Lesniak, MD, MHCM, FAANS; Daniel J. Brat, MD, PhD; John A. Kalapurakal MD, FACR, FASTRO; Vinai Gondi, MD; Chris Balmaceda, LCSW</td>
</tr>
<tr>
<td>10:55 - 11:25 AM</td>
<td><strong>Brain Tumor Network: Guiding and Empowering Patients and Caregivers</strong>&lt;br&gt;<strong>Presenting Sponsor:</strong> Sontag Foundation and Brain Tumor Network&lt;br&gt;Stephanie Gebhardt, DNP, APRN&lt;br&gt;Eden C. Mock, MSW, OPN-CGd&lt;br&gt;Patient navigation is still considered a relatively new term in the health care industry, measured by metrics and tools. This session explores the positive impacts of Brain Tumor Navigation through the metric that matters most: the patient experience.</td>
</tr>
</tbody>
</table>
11:25 - 11:30 AM CT  
**Break featuring:**

**Sponsor:**  
Orbus Therapeutics

**STELLAR Study: A Phase 3 Trial for Patients with Recurrent Anaplastic Astrocytoma**  
Kartik Aysola, MD

11:30 AM - 12:15 PM CT  
**Bench to Bedside: How Science Impacts Brain Tumor Patient Care**  
Shawn Hervey-Jumper, MD, FAANS, University of California San Francisco

Understand the importance of basic science research and how medical professionals apply this knowledge to brain tumor treatment and care.

12:15 - 1:00 PM CT  
**Lunch Session featuring:**

**Sponsor:**  
Monteris Medical

**The NeuroBlate System for Brain Tumors: A minimally invasive laser ablation procedure for brain tumors**  
Marty Emerson, CEO

Cleveland Clinic  
**Care and Treatment of Primary Brain Tumors: A multi-disciplinary approach to Primary Brain Tumors**  
Manmeet Ahluwalia, MD

GT Medical Technologies  
**GammaTile Therapy: A Head Start In The Fight Against Brain Tumors: Surgically Targeted Radiation Therapy For Brain Tumors**  
Kory Thomas, Regional Sales Director

**Research updates:**  
**Cytomegalovirus Oncomodulation of the Glioblastoma Tumor Environment**  
Christine O’Connor, PhD, *Cleveland Clinic*

**Validation of Diffusion MRI as a Predictive Imaging Biomarker for Anti-VEGF Therapies in Recurrent Glioblastoma**  
Benjamin Ellingson, PhD, *University of California, Los Angeles*

**Sponsors:**  
Advocate Children’s Midwest Brain Tumor Center  
**A Multidisciplinary Approach To Pediatric Patient Care**  
John Ruge, MD, Director of Pediatric Neurosurgery

Agios Pharmaceuticals  
**Introduction to Agios: Our Research in Low Grade Glioma**  
Susan Pandya MD, Vice President, *Clinical Development*
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 - 1:45 PM CT</td>
<td><strong>The Practical Approaches to Diagnosis &amp; Treatment of Brain Tumors</strong></td>
<td>Stefania Maraka, MD, <em>University of Illinois at Chicago</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Immerse in the understanding of diagnosis and treatment options for brain tumors, including recognizing the difference between primary and secondary brain tumors and current treatment options.</td>
</tr>
<tr>
<td>1:45 - 1:50 PM CT</td>
<td><strong>Break featuring:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Research update:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Repurposing Remyelination Drugs for Oligodendroglioma</em></td>
<td><em>Therapeutics</em></td>
</tr>
<tr>
<td></td>
<td>Yiping He, PhD, <em>Duke University Medical Center</em></td>
<td></td>
</tr>
<tr>
<td>1:50 - 2:35 PM CT</td>
<td><strong>Immunotherapy: Challenges and Opportunities for Brain Tumors</strong></td>
<td>Peter Fecci, MD, PhD, <em>Duke University Medical Center</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Learn about the current state of immunotherapy, its impact in brain tumor treatment, and the path to progress for treating primary and metastatic brain tumors.</td>
</tr>
<tr>
<td>2:35 - 2:40 PM CT</td>
<td><strong>Break featuring:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Research update:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Unraveling Regulatory T Cell-Dependent Anti-Tumor Mechanisms</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>in Brain Metastasis</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wei Du, MD, PhD, <em>Virginia Commonwealth University</em></td>
<td></td>
</tr>
<tr>
<td>2:40 - 3:10 PM CT</td>
<td><strong>Joel A. Gingras Jr. Award Presentation:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Introductions by: Jim Reilly, <em>ABTA Board Chair</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Marsha Gingras Baisch, <em>JAG Fund Board Member,</em></td>
<td><em>Chair of the JAG Gala</em></td>
</tr>
<tr>
<td></td>
<td>Priscilla Brastianos, MD, <em>Massachusetts General Hospital,</em></td>
<td><em>Harvard Medical School</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Since 2011, the ABTA has awarded the Joel A. Gingras Jr. Award to recognize an individual, organization or group that has made significant contributions to the Association's mission through philanthropy, advocacy, research, or patient care.</td>
</tr>
</tbody>
</table>
3:10 - 3:50 PM CT  **Keynote Session: Maria Menounos: Embodying the Role of Caregiver and Patient**
Maria Menounos, TV Host and CEO, *AfterBuzz TV*

Interviewed by: Mindee Plugues, *ABTA Chair, Mission Committee*

- Emmy® Award-winning journalist, author, actress and three-year brain tumor survivor Maria Menounos shares her personal experience, going from caregiver to patient. Maria will share personal insights on juggling public life while caring for her mother who was diagnosed with a glioblastoma brain tumor, and then turning her learnings inward as a patient and survivor of a meningioma brain tumor. Maria’s story shares encouragement and insights for others experiencing the brain tumor journey.

3:50 - 4:00 PM CT  **Closing Remarks**
Introductions by: Mindee Plugues, *ABTA Chair, Mission Committee*

- Susan Kramer, ABTA Co-Founder, *Honorary Board Member*

4:00 - 4:45 PM CT  **Optional: Social Hour for Current and Future Volunteers**
Alicia Morris, *ABTA Director, National Volunteers featuring ABTA Volunteers*

Join a fun, interactive hour with ABTA volunteers from all across the country! We will discuss all the great ways volunteers can spread awareness and get involved in their communities.

---

**Saturday, September 12**

10:00 - 10:10 AM  **Welcome**
Ralph DeVitto, *ABTA President & CEO*

- Don and Gail Segal, *ABTA Honorary Board Members*

10:10 - 11:20 AM CT  **Brain Tumor Board**

Listen in as a multi-disciplinary panel of expert clinicians simulate the review of brain tumor cases to determine the best course of treatment for patients.

**Facilitator:**
Mark R. Gilbert, MD, *Center for Cancer Research, National Cancer Institute, National Institutes of Health*
Panelists:
Evanthia Galanis, MD, Mayo Clinic
Shawn Hervey-Jumper, MD, FAANS, University of California San Francisco
Jason T. Huse, MD, PhD, MD, Anderson Cancer Center
Vijay Ramaswamy, MD, PhD, FRCP, Hospital for Sick Children, University of Toronto
Jennifer Yu, MD, PhD, Cleveland Clinic

11:20 - 11:25 AM CT  Break featuring:

Sponsors:
NeuroD1 Dictates Tumor Cell Differentiation in Medulloblastoma
Zeng-jie Yang, MD, PhD, The Research Institute at Fox Chase Cancer Center

11:25 - 12:10 PM CT  The Importance of Patient Outcomes Assessments in Determining Optimal Treatment
Terri S. Armstrong, PhD, ANP-BC, FAAN, FAANP
Center for Cancer Research, National Cancer Institute

Assessing a patient’s progress against the initial treatment plan (patient outcomes) is an essential step in care. This session covers the needs and benefits of evaluating outcomes for the patient, scientific progress and development of new treatments.

12:10 - 1:10 PM CT  Lunch Break featuring:

Meet the ABTA Board of Directors:
Jim Reilly, Chair
Brandon Starkoff, Vice Chair
Carla Varner, Secretary
Susannah Davis, Director
Bob Kruchten, Chair, Development Committee
Jacqueline Lemke, Director
Mindee Plugues, Chair, Mission Committee

Meet the ABTA Board Members and hear why they are involved with ABTA and passionate about the Mission.

Sponsors:
Karyopharm Therapeutics
Selinexor in GBM: XPORT-GBM-029. A Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Jatin Shah MD, CMO

NorthShore University Health System
NorthShore Neurological Institute’s Brain Tumor Program: Procedures, Innovations, Clinical Trials, and a Multispecialty Team
Ryan Merrell, MD
Research updates:
A Novel Pressure-Reducing Therapy to Abrogate Tumor Invasiveness and Immune Infiltration in Glioblastoma
Hanna Sabelstrom, PhD, University of California, San Francisco

Microcircuit Platform to Screen Ion Channel Blockers for Medulloblastoma
Min Tang-Schomer, PhD, The Jackson Laboratory for Genomic Medicine

Programming Tumor-Clearing Macrophages with Targeted Gene Therapy
Fan Zhang, PhD, Fred Hutchinson Cancer Research Center

Sponsors:
Northwest Biotherapeutics
DCVax® Personalized Immune Therapies: Explanation of what dendritic cell therapies (such as DCVax) are, how they work and how they are different from other kinds of treatments for GBM.
Ms. Linda Powers, CEO

Elekta
Zero in on Brain Metastases: Leksell Gamma Knife Icon
Sean Looney, Director of Business Marketing Neuroscience

Novocure
Thought Leader Liaison: An FDA Approved treatment for Glioblastoma
Renae Adams, Thought Leader Liaison

1:10 - 1:55 PM CT
Clinical Trials: A Primer
Mark R. Gilbert, MD, Center for Cancer Research, National Cancer Institute, National Institutes of Health

Participation in clinical trials can offer patients and families access to novel brain tumor treatments. This session offers attendees ground-level strategies in considering clinical trials.

1:55 - 2:20 PM CT
Clinical Trials: Panel Discussion with Experts

This panel has been designed to allow world-renowned clinical study experts to give their perspectives on the current state and future directions of clinical research for patients with brain and spinal cord tumors. Importantly, hear from the patient perspective from a patient who has participated in brain tumor clinical trials.
**Facilitator:**
Mark R. Gilbert, MD, Center for Cancer Research, National Cancer Institute, National Institutes of Health

**Panelists:**
Terri S. Armstrong, PhD, ANP-BC, FAAN, FAAN, Center for Cancer Research, National Cancer Institute
Jean Arzbaecher, RN, APN, CNRN, The University of Illinois at Chicago
Peter Fecchi, MD, PhD, Duke University Medical Center
Evanthia Galanis, MD, Mayo Clinic
Donna Van Ryn, clinical trial patient

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:20 - 2:25 PM CT</td>
<td>Break featuring:</td>
</tr>
<tr>
<td>2:25 - 3:10 PM CT</td>
<td><strong>Holistic Management of Brain Tumor Symptoms</strong></td>
</tr>
<tr>
<td></td>
<td>Roy E. Strowd III, MD, Med, MS, Wake Forest School of Medicine</td>
</tr>
<tr>
<td></td>
<td>Learn about common brain tumor symptoms during the phases of treatment as well as complementary approaches and interventions such as cannabis, acupuncture and other therapies.</td>
</tr>
<tr>
<td>3:10 - 3:15 PM CT</td>
<td>Break featuring:</td>
</tr>
<tr>
<td>3:15 - 4:00 PM CT</td>
<td><strong>Caring for The Caregiver</strong></td>
</tr>
<tr>
<td></td>
<td>Jean Arzbaecher, RN, APN, CNRN, The University of Illinois at Chicago</td>
</tr>
<tr>
<td></td>
<td>A brain tumor diagnosis is a life-changing event, not only for the patient, but also for family members and loved ones. This session will explore the many roles of caregivers and identify strategies and resources to facilitate the process of caregiving.</td>
</tr>
<tr>
<td>4:00 - 4:05 PM CT</td>
<td>Break featuring:</td>
</tr>
<tr>
<td></td>
<td><strong>Targeting TLR2 in EGFR/EGFRvIII+ Glioblastoma</strong></td>
</tr>
<tr>
<td></td>
<td>Zhenyi An, PhD, University of California, San Francisco</td>
</tr>
</tbody>
</table>
4:05 - 4:50 PM CT  Living with a Brain Tumor: Patient and Caregiver Panel

Learn key strategies and approaches to navigate your brain tumor journey or that of your loved one in this lively and interactive brain tumor patient and caregiver panel. Get ideas for how to cope and where to find resources and support.

**Facilitator:** Jean Arzbaecher, RN, APN, CNRN, *The University of Illinois at Chicago*

**Patient and Caregiver Panelists:**
- Donna and Paul Van Ryn
- Aisha Khalid Khan and Khola Shuaib
- Steffanie and Scott Flack

4:50 - 5:00 PM CT  Closing Comments & Adjournment

Ralph DeVitto, *ABTA President & CEO*

Jim Reilly, *ABTA Board Chair*
# Maximizing Your Conference Experience

Here are some tips to make the ABTA National Conference an enjoyable and educational experience. Free registration at [www.abta.org/national-conference](http://www.abta.org/national-conference) is required to access presentations, sessions and ask questions with speakers.

| GETTING THE MOST OUT OF THE CONFERENCE | 1) Find a comfortable and quiet space to focus.  
2) Plan to enter the conference 15 minutes before the first session to get familiar with navigating the virtual platform.  
3) Plan ahead and choose the sessions you want to join in advance.  
4) Have a notebook and pen handy to capture notes from each session. |
| --- | --- |
| PRIOR TO THE CONFERENCE, DOWNLOAD AND CREATE A ZOOM ACCOUNT | We will be using Zoom as our virtual platform. Prior to the conference:  
1) Download Zoom Software: You will need to have the Zoom software, associated to your email address, on the device being used to participate in the conference. Zoom is a free software that works on a laptop/PC; Android phone; iPad or iPhone.  
2) Create Zoom Account: Create a Zoom account using the same email address you used to register for the meeting. Follow these instructions to download and sign up  
On a PC/Laptop go to [https://zoom.us/download](https://zoom.us/download).  
   o Download ‘Zoom Client for Meetings’  
   o Follow the instructions to Sign-up for Zoom  
On an Android Phone go to the Play Store.  
   o Search ‘Zoom’  
   o Install ‘ZOOM Cloud Meetings’  
   o Follow the instructions to Sign-up for Zoom  
On an iPad or iPhone go to the App Store  
   o Search ‘Zoom’  
   o Install ‘ZOOM Cloud Meetings’  
   o Follow the instructions to Sign-up for Zoom |
| CONFERENCE LINK AND JOIN TIME | You will join the conference using the link/teleconference information provide a few days before the conference. Please join the Zoom meeting at least 15 minutes before the program or session start time. All presentations will take place in Central Time Zone. |
| ASKING QUESTIONS DURING THE CONFERENCE | You will have an opportunity to submit questions anonymously after the presentation using the control panel on the bottom of your Zoom screen. Click on “Q&A” and type in your question. Our speakers will try to answer as many questions as time allows. |
| PRESENTATION AUDIO/VIDEO | You will be able to hear and see presentations and the speakers during the conference. However, your own device audio and video will be muted throughout the meeting. |
| ENSURE A SMOOTH CONNECTION TO THE CONFERENCE | If using a desktop or laptop computer, connect your device to a hard-wired Internet connection (not Wi-Fi) and running at high-speed. Ensure all applications or any programs with notifications, pop-ups or reminders are closed (e.g., Outlook, chat, calendar applications). |
CONFERENCE CO-CHAIR GREETING

Dear Conference Attendees,

We want to give you our sincerest welcome to the American Brain Tumor Association 2020 National Conference. We recognize that the current situation prevents us from gathering together and we know that those who have participated in prior conferences share our disappointment in not being able to network in person. However, we are both pleased and excited to provide an outstanding program designed to inform and support you along your journey. Lecture topics will discuss treatment advancements for a variety of brain tumors, strategies to manage day-to-day symptoms and concerns, survivorship, emerging technologies, and much more.

Although the meeting will be virtual, we are encouraging you to be fully engaged. In that context, we invite you to ask questions and share your experiences throughout the conference. As you can see from the Program, the conference includes other invaluable experiences, including a variety of educational resources from our sponsors, poster presentations from our researchers, an opportunity to hear from patients and caregivers as they live with a brain tumor, and a Keynote speaker Maria Menounos, Emmy® Award-winning journalist, author, actress and brain tumor survivor. We hope this conference will be an invaluable and enriching experience.

Thank you so much for participating. We look forward to spending time with you.

Sincerely,

ABTA National Conference Co-Chairs
Mark R. Gilbert, MD and Jean Arzbaecher, RN, APN, CNRN
The American Brain Tumor Association thanks our generous sponsors.

Funded in part by

Genentech
Integra Foundation
CONFERENCE CO-CHAIR GREETING

Dear Conference Attendees,

We want to give you our sincerest welcome to the American Brain Tumor Association 2020 National Conference. We recognize that the current situation prevents us from gathering together and we know that those who have participated in prior conferences share our disappointment in not being able to network in person. However, we are both pleased and excited to provide an outstanding program designed to inform and support you along your journey. Lecture topics will discuss treatment advancements for a variety of brain tumors, strategies to manage day-to-day symptoms and concerns, survivorship, emerging technologies, and much more.

Although the meeting will be virtual, we are encouraging you to be fully engaged. In that context, we invite you to ask questions and share your experiences throughout the conference. As you can see from the Program, the conference includes other invaluable experiences, including a variety of educational resources from our sponsors, poster presentations from our researchers, an opportunity to hear from patients and caregivers as they live with a brain tumor, and a Keynote speaker Maria Menounos, Emmy® Award-winning journalist, author, actress and brain tumor survivor. We hope this conference will be an invaluable and enriching experience.

Thank you so much for participating. We look forward to spending time with you.

Sincerely,

ABTA National Conference Co-Chairs
Mark R. Gilbert, MD and Jean Arzbaecher, RN, APN, CNRN

A BRAIN TUMOR DIAGNOSIS CAN BE LIFE-CHANGING

AT Brain Tumor Network We're Here For You

Request a consultation at BrainTumorNetwork.org or call (844) 286-6110 to learn about our no-cost personalized navigation services available to help you and your family take the next steps
AGIOS IS A PROUD SPONSOR OF THE
AMERICAN BRAIN TUMOR ASSOCIATION

At Agios, we are guided by a deep-rooted commitment by creating treatment options that make a meaningful difference in patients’ lives and fundamentally change the way cancer is treated.
“I didn’t think I’d be alive today. Now here I am with Optune, still enjoying life.”

- Marcia, an Optune user

Optune® is a wearable, portable FDA-approved treatment for glioblastoma (GBM)

What is Optune approved to treat?
Optune is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.

Newly diagnosed GBM
If you have newly diagnosed GBM, Optune is used together with a chemotherapy called temozolomide (TMZ) if:
• Your cancer is confirmed by your healthcare professional AND
• You have had surgery to remove as much of the tumor as possible

Recurrent GBM
If your tumor has come back, Optune can be used alone as an alternative to standard medical therapy if:
• You have tried surgery and radiation and they did not work or are no longer working AND
• You have tried chemotherapy and your GBM has been confirmed by your healthcare professional.

Who should not use Optune?
Optune is not for everyone. Talk to your doctor if you have:
• An implanted medical device (programmable shunt), skull defect (missing bone with no replacement), or bullet fragment. Optune has not been tested in people with implanted electronic devices, which may cause the devices not to work properly, and Optune has not been tested in people with skull defects or bullet fragments, which may cause Optune not to work properly
• A known sensitivity to conductive hydrogels (the gel on the arrays placed on the scalp like the ones used on EKGs). When Optune comes into contact with the skin, it may cause more redness and itching or may rarely cause a life-threatening allergic reaction.

Do not use Optune if you are pregnant or are planning to become pregnant. It is not known if Optune is safe or effective during pregnancy.

What should I know before using Optune?
Optune should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure®, the maker of Optune.
• Do not use any parts that did not come with the Optune Treatment Kit sent to you by Novocure or given to you by your doctor
• Do not get the device or transducer arrays wet
• If you have an underlying serious skin condition on the scalp, discuss with your doctor whether this may prevent or temporarily interfere with Optune treatment

What are the possible side effects of Optune?
Most common side effects when using Optune alone were scalp irritation (redness and itchiness) and headache. Other side effects were malaise, muscle twitching, fall and skin ulcers. Talk to your doctor if you have any of these side effects or questions.

Please visit Optune.com/Safety for the Optune Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions. Patient image reflects the health status of the patient at the time the photo was taken.
World-Class Care for Brain Tumors

At Northwestern Medicine, we combine innovative and compassionate care with a relentless search for cures, all to improve the lives of patients with cancer. Anchored by Northwestern Memorial Hospital, ranked No. 5 in the U.S. for Neurology and Neurosurgery, and No. 8 in the U.S. for Cancer care by U.S. News & World Report, 2020-2021, you have access to the latest treatments and technology, as well as to many pioneering brain tumor clinical trials downtown and in the western and northern suburbs. Each treatment plan is designed by a team of experts in medical oncology, radiation oncology, neuro-oncology, neurology, neurological surgery, neuropathology and neuroradiology, tailored to your needs and specific to the tumor to be treated.

Learn more at nm.org/braintumor.

Northwest Biotherapeutics is honored to be a part of the American Brain Tumor Association’s 2020 National Conference and invites you to visit our website for further information about our DCVax® Personalized Immune Therapies

www.nwbio.com
SDP Oncology is proud to support the American Brain Tumor Association and its efforts to advocate for the brain tumor community.

Sumitomo Dainippon Pharma Oncology

SDPOncology.com

The STELLAR Trial

A phase 3 clinical trial now recruiting patients with recurrent anaplastic astrocytoma at centers in North America and Europe

www.stellarstudy.com
CONFERENCE CO-CHAIR GREETING

Dear Conference Attendees,

We want to give you our sincerest welcome to the American Brain Tumor Association 2020 National Conference. We recognize that the current situation prevents us from gathering together and we know that those who have participated in prior conferences share our disappointment in not being able to network in person. However, we are both pleased and excited to provide an outstanding program designed to inform and support you along your journey. Lecture topics will discuss treatment advancements for a variety of brain tumors, strategies to manage day-to-day symptoms and concerns, survivorship, emerging technologies, and much more.

Although the meeting will be virtual, we are encouraging you to be fully engaged. In that context, we invite you to ask questions and share your experiences throughout the conference. As you can see from the Program, the conference includes other invaluable experiences, including a variety of educational resources from our sponsors, poster presentations from our researchers, an opportunity to hear from patients and caregivers as they live with a brain tumor, and a Keynote speaker Maria Menounos, Emmy® Award-winning journalist, author, actress and brain tumor survivor. We hope this conference will be an invaluable and enriching experience.

Thank you so much for participating. We look forward to spending time with you.

Sincerely,

ABTA National Conference Co-Chairs
Mark R. Gilbert, MD and Jean Arzbaecher, RN, APN, CNRN

MOTHERS OF PRACTICALITY
The NeuroBlate® System, for the ablation of brain lesions, is a minimally invasive robotically controlled directional laser tool delivering transformative neurological solutions without the invasiveness of an open neurological procedure. monteris.com/patients-caregivers/

Rx Only.

OFFERING HOPE TO PATIENTS

NeuroBlate® System

For people with brain tumors

Specifically designed to treat operable brain tumors, GammaTile Surgically Targeted Radiation Therapy (STaRT) is tough on the tumor and easier on you and your caregivers. It eliminates the need for traditional repeat radiation treatments so you can focus on what matters most—healing.

Learn more at gammatile.com.

For full product and safety information, refer to the Instructions for Use.
CONFERENCE CO-CHAIR GREETING

Dear Conference Attendees,

We want to give you our sincerest welcome to the American Brain Tumor Association 2020 National Conference. We recognize that the current situation prevents us from gathering together and we know that those who have participated in prior conferences share our disappointment in not being able to network in person. However, we are both pleased and excited to provide an outstanding program designed to inform and support you along your journey. Lecture topics will discuss treatment advancements for a variety of brain tumors, strategies to manage day-to-day symptoms and concerns, survivorship, emerging technologies, and much more.

Although the meeting will be virtual, we are encouraging you to be fully engaged. In that context, we invite you to ask questions and share your experiences throughout the conference. As you can see from the Program, the conference includes other invaluable experiences, including a variety of educational resources from our sponsors, poster presentations from our researchers, an opportunity to hear from patients and caregivers as they live with a brain tumor, and a Keynote speaker Maria Menounos, Emmy® Award-winning journalist, author, actress and brain tumor survivor. We hope this conference will be an invaluable and enriching experience.

Thank you so much for participating. We look forward to spending time with you.

Sincerely,

ABTA National Conference Co-Chairs
Mark R. Gilbert, MD and Jean Arzbaecher, RN, APN, CNRN

---

At NorthShore Neurological Institute, we’re advancing care for brain tumors and other neurological challenges. From the latest in minimally invasive brain surgery to analyzing the genetic makeup of tumors. At NorthShore, we’re providing answers to improve odds—and lives.

northshore.org/neuro
(877) 570-7020

NorthShore University HealthSystem
Neurological Institute
Dear Conference Attendees,

We want to give you our sincerest welcome to the American Brain Tumor Association 2020 National Conference. We recognize that the current situation prevents us from gathering together and we know that those who have participated in prior conferences share our disappointment in not being able to network in person. However, we are both pleased and excited to provide an outstanding program designed to inform and support you along your journey. Lecture topics will discuss treatment advancements for a variety of brain tumors, strategies to manage day-to-day symptoms and concerns, survivorship, emerging technologies, and much more.

Although the meeting will be virtual, we are encouraging you to be fully engaged. In that context, we invite you to ask questions and share your experiences throughout the conference. As you can see from the Program, the conference includes other invaluable experiences, including a variety of educational resources from our sponsors, poster presentations from our researchers, an opportunity to hear from patients and caregivers as they live with a brain tumor, and a Keynote speaker Maria Menounos, Emmy® Award-winning journalist, author, actress and brain tumor survivor. We hope this conference will be an invaluable and enriching experience.

Thank you so much for participating. We look forward to spending time with you.

Sincerely,

ABTA National Conference Co-Chairs
Mark R. Gilbert, MD and Jean Arzbaecher, RN, APN, CNRN
CONFERENCE CO-CHAIR GREETING

Dear Conference Attendees,

We want to give you our sincerest welcome to the American Brain Tumor Association 2020 National Conference. We recognize that the current situation prevents us from gathering together and we know that those who have participated in prior conferences share our disappointment in not being able to network in person. However, we are both pleased and excited to provide an outstanding program designed to inform and support you along your journey. Lecture topics will discuss treatment advancements for a variety of brain tumors, strategies to manage day-to-day symptoms and concerns, survivorship, emerging technologies, and much more.

Although the meeting will be virtual, we are encouraging you to be fully engaged. In that context, we invite you to ask questions and share your experiences throughout the conference. As you can see from the Program, the conference includes other invaluable experiences, including a variety of educational resources from our sponsors, poster presentations from our researchers, an opportunity to hear from patients and caregivers as they live with a brain tumor, and a Keynote speaker Maria Menounos, Emmy® Award-winning journalist, author, actress and brain tumor survivor. We hope this conference will be an invaluable and enriching experience.

Thank you so much for participating. We look forward to spending time with you.

Sincerely,

ABTA National Conference Co-Chairs
Mark R. Gilbert, MD and Jean Arzbaecher, RN, APN, CNRN
THANK YOU